Related Experiment Video
Updated: Mar 10, 2026
Isolation of Perivascular Multipotent Precursor Cell Populations from Human Cardiac Tissue
Published on: October 8, 2016
Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery
Georgina M Ellison-Hughes1, Paolo Madeddu2
1Centre of Human & Aerospace Physiological Sciences, Centre for Stem Cells and Regenerative Medicine, Faculty of Medicine & Life Sciences, Guy's Campus, King's College London, London SE1 1UL, United Kingdom.
Insights
Cardiovascular regenerative medicine explores stem cell secretomes for treating ischaemic diseases. Off-the-shelf stem cell products and secretome derivatives offer scalable, commercially viable therapeutic potential.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Biotechnology
Background:
- Ischaemic diseases represent a significant global health burden, with current treatments offering symptomatic relief but lacking definitive tissue repair.
- Advancements in cardiovascular regenerative medicine focus on restorative approaches like gene therapy, stem cell therapy, and tissue engineering.
- Stem cell transplantation shows promise, with indirect actions via secreted factors influencing endogenous repair mechanisms.
Purpose of the Study:
- To review the paracrine properties of cardiac stem cells and pericytes for cardiovascular regenerative medicine.
- To highlight the potential of stem cell secretome derivatives as scalable, off-the-shelf therapeutic products.
- To discuss the commercial and medical benefits of developing novel cardiovascular drugs based on stem cell secretome refinement.
Main Methods:
- Literature review focusing on stem cell secretome and paracrine signaling.
- Analysis of cardiac stem cells and pericytes as therapeutic sources.
- Evaluation of the scalability and commercial potential of cell-based therapies and secretome derivatives.
Main Results:
- Stem cell secretome, particularly from cardiac stem cells and pericytes, exhibits significant paracrine effects beneficial for ischaemic tissue repair.
- Off-the-shelf stem cell products and secretome derivatives demonstrate greater potential for large-scale distribution and commercial investment compared to autologous therapies.
- The paracrine properties of stem cells are key to their therapeutic efficacy in cardiovascular regenerative medicine.
Conclusions:
- Stem cell secretome refinement offers a promising avenue for developing next-generation cardiovascular drugs.
- Off-the-shelf stem cell products and secretome derivatives present a viable strategy for addressing the limitations of autologous stem cell therapies.
- Further research into the paracrine mechanisms of cardiac stem cells and pericytes can drive innovation in treating ischaemic cardiovascular disorders.
Abstract:
Ischaemic diseases remain a major cause of morbidity and mortality despite continuous advancements in medical and interventional treatments. Moreover, available drugs reduce symptoms associated with tissue ischaemia, without providing a definitive repair. Cardiovascular regenerative medicine is an expanding field of research that aims to improve the treatment of ischaemic disorders through restorative methods, such as gene therapy, stem cell therapy, and tissue engineering. Stem cell transplantation has salutary effects through direct and indirect actions, the latter being attributable to growth factors and cytokines released by stem cells and influencing the endogenous mechanisms of repair. Autologous stem cell therapies offer less scope for intellectual property coverage and have limited scalability. On the other hand, off-the-shelf cell products and derivatives from the stem cell secretome have a greater potential for large-scale distribution, thus enticing commercial investors and reciprocally producing more significant medical and social benefits. This review focuses on the paracrine properties of cardiac stem cells and pericytes, two stem cell populations that are increasingly attracting the attention of regenerative medicine operators. It is likely that new cardiovascular drugs are introduced in the next future by applying different approaches based on the refinement of the stem cell secretome.
